



MEDICAL TIPS

LOSTAT Tablets

Issue VI, No.23, 2023

Effects of losartan in patients with NAFLD: A meta-analysis of randomized controlled trial

Meng C, et al. Open Life Sci. 2023; 18(1): 20220583.

- Non-alcoholic fatty liver disease (NAFLD) is a progressive disease and it is known that alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are indicators of the degree of hepatocyte damage.
- In some studies, angiotensin receptor blockers (ARBs) have been found to regulate hepatic lipid and few have observed that Losartan may play a role in reducing transaminase in NAFLD population.
- The present meta-analysis (6 trails, 408 patients) examined the effects Losartan in NAFLD.
- It demonstrated that AST was significantly affected by Losartan therapy and that Losartan 50 mg once daily lowered the level of ALT, ($P < 0.01$) respectively.

Losartan 50 mg once daily can significantly improve the liver function of NAFLD patients.

